TY - JOUR
T1 - Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2 seropositive persons during early HIV-1 infection
AU - Nina Kim, H.
AU - Wang, Jing
AU - Hughes, James
AU - Coombs, Robert
AU - Sanchez, Jorge
AU - Reid, Stewart
AU - Delany-Moretlwe, Sinead
AU - Cowan, Frances
AU - Fuchs, Jonathan
AU - Eshleman, Susan H.
AU - Khaki, Leila
AU - McMahon, Moira A.
AU - Siliciano, Robert F.
AU - Wald, Anna
AU - Celum, Connie
PY - 2010/9/1
Y1 - 2010/9/1
N2 - We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse- transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons(HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (Pp.30) or CD4 cell counts (Pp.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.
AB - We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse- transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons(HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (Pp.30) or CD4 cell counts (Pp.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.
U2 - 10.1086/655662
DO - 10.1086/655662
M3 - Article
VL - 202
SP - 734
EP - 738
JO - Journal of Infectious Disease
JF - Journal of Infectious Disease
IS - 5
ER -
